Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C275982-5mg | 5mg | In stock | $75.90 | |
C275982-25mg | 25mg | In stock | $342.90 | |
C275982-100mg | 100mg | In stock | $489.90 | |
C275982-500mg | 500mg | In stock | $1,360.90 | |
C275982-1g | 1g | In stock | $1,795.90 |
Potent, broad spectrum stemness high-cancer cell inhibitor
Synonyms | NAPABUCASIN [WHO-DD] | NSC788900 | (Indole-3-yl)acetonitrile | CCG-20461 | D10717 | EC 423-800-5 | AKOS027470201 | CS-1747 | NAPHTHO(2,3-B)FURAN-4,9-DIONE, 2-ACETYL- | 2-Acetyl-naphtho[2,3-b]furan-4,9-dione | Napabucasin; BBI608 | UNII-Z1HHM49K7O | SCHEMB |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Potent, broad spectrum stemness high-cancer cell inhibitor (IC 50 values are 500 - 1200 nM). Inhibits STAT3-driven gene transcription. Potently prevents self-renewal in cancer stem cells. Shows antineoplastic and antimetastatic effects in vivo. |
Source | Synthetic |
Storage Temp | Store at -20°C,Desiccated |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. |
ALogP | 2.3 |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488196633 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488196633 |
IUPAC Name | 2-acetylbenzo[f][1]benzofuran-4,9-dione |
INCHI | InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3 |
InChi Key | DPHUWDIXHNQOSY-UHFFFAOYSA-N |
Canonical SMILES | CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O |
Isomeric SMILES | CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O |
PubChem CID | 10331844 |
Molecular Weight | 240.21 |
PubChem CID | 10331844 |
---|---|
CAS Registry No. | 83280-65-3 |
ChEMBL Ligand | CHEMBL64130 |
BindingDB Ligand | 50366597 |
PubChem SID | 488196633 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C2412026 | Certificate of Analysis | Feb 20, 2024 | C275982 |
D2325463 | Certificate of Analysis | Feb 20, 2024 | C275982 |
D2325464 | Certificate of Analysis | Feb 20, 2024 | C275982 |
D2325468 | Certificate of Analysis | Feb 20, 2024 | C275982 |
D2325470 | Certificate of Analysis | Feb 20, 2024 | C275982 |
D2325471 | Certificate of Analysis | Jan 31, 2024 | C275982 |
D2325477 | Certificate of Analysis | Jan 31, 2024 | C275982 |
D2325481 | Certificate of Analysis | Jan 31, 2024 | C275982 |
D2325489 | Certificate of Analysis | Jan 31, 2024 | C275982 |
D2325490 | Certificate of Analysis | Jan 31, 2024 | C275982 |
D2325488 | Certificate of Analysis | Mar 27, 2023 | C275982 |
Solubility | Soluble in DMSO |
---|---|
Sensitivity | Heat Sensitive |
Melt Point(°C) | 226 °C |
1. Bao N, Ou J, Xu M, Guan F, Shi W, Sun J, Chen L. (2017) Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.. Eur J Med Chem, 137 (13): (88-95). [PMID:28558333] [10.1021/op500134e] |
2. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ. (2015) Suppression of cancer relapse and metastasis by inhibiting cancer stemness.. Proc Natl Acad Sci U S A, 112 (6): (1839-44). [PMID:25605917] [10.1021/op500134e] |
3. Zhou Q, Peng C, Du F, Zhou L, Shi Y, Du Y, Liu D, Sun W, Zhang M, Chen G. (2018) Design, synthesis and activity of BBI608 derivatives targeting on stem cells.. Eur J Med Chem, 151 (13): (39-50). [PMID:29604543] [10.1021/op500134e] |
4. Löcken H, Clamor C, Müller K. (2018) Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.. J Nat Prod, 81 (7): (1636-1644). [PMID:30003778] [10.1021/op500134e] |
5. Han D, Yu T, Dong N, Wang B, Sun F, Jiang D. (2019) Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.. J Exp Clin Cancer Res, 38 (1): (289). [PMID:31277685] [10.1021/op500134e] |
6. Chowdhury KH, Chowdhury MR, Mahmud S, Tareq AM, Hanif NB, Banu N, Reza ASMA, Emran TB, Simal-Gandara J. (2020) Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.. Biology (Basel), 10 (1): (1755-70). [PMID:33374717] [10.3390/biology10010002] |
7. Hubbard JM, Grothey A. (2017) Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.. Drugs, 77 (10): (1091-1103). [PMID:28573435] [10.1021/op500134e] |